The latest update is out from Ocular Therapeutix (OCUL).
Ocular Therapeutix, Inc. stockholders have greenlit significant changes that will shape the company’s future. They’ve approved an amendment to the 2021 Stock Incentive Plan, allowing for an additional 7 million shares to be issued, effectively doubling the authorized common stock to 400 million shares. Additionally, Adrienne L. Graves, Ph.D., and Charles Warden were elected as directors, executive compensation was endorsed, and PricewaterhouseCoopers LLP was ratified as the company’s independent accounting firm for the upcoming fiscal year. These decisions reflect shareholder confidence and pave the way for strategic growth initiatives.
For detailed information about OCUL stock, go to TipRanks’ Stock Analysis page.
